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The design, preparation and evaluation of biodegradable ionic liquids containing ester or amide groups in the alkyl side
chain are presented. Factors improving the biodegradation of surfactants were successfully applied to ionic liquids. These
novel ionic liquids can be prepared from readily available starting materials in high yield. The introduction of a group
susceptible to enzymatic hydrolysis greatly improves the biodegradation (OECD 301D ‘Closed Bottle Test’) compared
with the commonly used dialkylimidazolium ionic liquids, bmimBF4 and bmimPF6. For the
3-methyl-1-(alkyloxycarbonylmethyl)imidazolium bromide series, the greatest biodegradation was observed when alkyl
= butyl, pentyl, hexyl and octyl. The corresponding amide analogs proved to be poorly biodegradable.
Introduction
Ionic liquids (ILs) have been the subject of considerable interest as
media for a wide range of synthetic and analytical processes.1,2
They are considered in a ‘green chemistry’ context due to their low
vapour pressure, ease of recovery facilitating recycling3 and
applicability to catalytic processes.4 ILs possess a number of
interesting properties such as high polarity and ionic conductivity,
a wide window of electrochemical potential and excellent chemical
and thermal stability. However, it is this stability that has lead us to
question the potential for ILs to accumulate in the environment.5
When the ionic liquid has served its operational use, disposal
becomes an issue. As the pressure to reduce incineration and
landfill waste increases the requirement for chemicals which are
biodegradable increases.6 Within the field of green chemistry it is
unacceptable to produce large quantities of waste which have high
ecotoxicity or biological activity.7 Seddon reported the first
industrial process where ionic liquids were used on a multi-tonne
scale.8 As ionic liquids advance from academic curiosities the need
to study their toxicity and biodegradation is paramount.
Toxicity to humans and other organisms has obvious sig-
nificance, while toxicity to micro organisms has the potential to
limit biodegradation. Like biodegradability, the assessment of IL
toxicity is only now being addressed. There have been a few articles
stating that there is a need to test the biodegradation of ionic
liquids5 however experimental results to ascertain these properties
have been surprisingly lacking.
In a preliminary communication9 we reported the first investiga-
tion into the biodegradability of the dialkylimidazolium ionic
liquids. We chose the dialkylimidazolium ILs as a starting point and
incorporated features which have been found to improve the
biodegradability of other classes of compounds such as surfactants.
Since this initial disclosure of our findings no biodegradation data
on ILs has been published, although a few preliminary toxicology
results have been reported.
Jastorff and co-workers subsequently reported a theoretical
environment risk analysis on a test set of dialkylimidazolium ILs.10
This multidimensional analysis was based on five ecotoxicological
indicators; release, spatiotemporal range, bioaccumulation, bio-
logical activity and uncertainty. The current lack of detailed
experimental data on the biodegradability of ILs complicated
predictions on bioaccumulation and spatiotemporal range and
resulted in a high uncertainty level.
Our inspiration for this work came from the development of
biodegradable surfactants. We now report our progress towards
preparing a readily biodegradable ionic liquid.
History of surfactants
The development of biodegradable surfactants11 has been of
significant commercial interest since the 1940’s when synthetic
surfactants were developed as a replacement for soap in many
laundry products. Tetrapropylene alkyl benzene sulfonates
(TPBS)12 were manufactured extensively but due to their poor
biodegradation lead to major problems in sewage treatment and
contamination of river waters.13
Modification of the highly branched alkyl chain to the linear
secondary alkyl group gave linear alkylbenzene sulfonate surfac-
tants (LAS) with greatly improved biodegradation.14 In the 1960’s
TPBS were phased out and replaced with LAS in the United
States.12
On further examination of the literature regarding biodegrada-
tion of surfactant compounds we noticed a close resemblance
between many quaternary ammonium compounds as well as
surfactants based around an imidazolium core. These derivatives
have a striking resemblance to the structure of many of the most
important ILs prepared to date and we felt that much of the work
developing biodegradable surfactants would be relevant to the
design of a biodegradable ionic liquid. In particular is the
development of biodegradable surface active quaternary ammo-
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nium compounds (QACs). The most popular QAC used initially
was the dialkyl dimethyl ammonium salt (1), however the
biodegradation of 1 in aquatic sediments is low and this coupled to
its ecotoxicity has led to its replacement by dialkyl QACs based on
the imidazolium and ethoxylated ethanaminium QACs (compounds
2 and 3).15 The presence of the amide bonds led to improved
biodegradation properties due to an extra hydrolysis degradation
pathway. Ester derivatives (4 and 5) and related compounds have
also been prepared and show good biodegradation.15,16c
Design
Boethling15 identified three factors which are important in the
design of biodegradable compounds; (i) the presence of potential
sites of enzymatic hydrolysis (for example, esters and amides), (ii)
the introduction of oxygen in the form of hydroxyl, aldehyde or
carboxylic acid groups, and (iii) the presence of unsubstituted linear
alkyl chains (especially 44 carbons) and phenyl rings, which
represent possible sites for attack by oxygenases. These principles
have been followed during the development of biodegradable
surfactants.16–18
Not all of these structural features are appropriate for ILs. The
incorporation of oxygen containing functional groups such as
alcohols, aldehyde and carboxylic acids would severely limit the
ILs usefulness as reaction media, while the introduction of phenyl
groups is known to produce compounds with elevated melting
points.19 As a result, we chose to prepare dialkylimidazolium ILs
with ester or amide functionality in one of the side chains. It was
deemed important to limit branching in the side chains so only
linear alkyl groups attached to the ester and amide were chosen. An
important feature of this design is that although there are a very
large number of possible ionic liquids that can theoretically be
prepared based on the imidazolium core, within the limits
suggested in the design segment of this paper, the number of
potential hot targets is reasonably small. The incorporation of an
ester or amide group was postulated to be a balance between
reduced chemical stability and increased biodegradability.
A major concern at the design stage of this project was the
physical properties of these modified imidazolium ionic liquids.
Points which needed to be addressed were 1) melting points and 2)
solubility and the effect of the ester/amide alkyl length on these
properties. If the inclusion of an ester or amide bond into the side
chain lead to increased order and crystallinity these target ionic
liquids would only be liquids at elevated temperatures. A key
property of PF6 and NTf2 based ILs is their hydrophobic nature. If
the hydrogen bonding possible with the ester or amide in the side
chain was sufficient to remove this hydrophobic character then their
use as alternatives for BmimPF6 and BmimNTf2 would be
compromised.
Results and discussion
Syntheses of the ILs described in this manuscript were based on
standard approaches for the preparation of imidazolium ILs.19,20
This process involved alkylation of methyl imidazole with the
appropriate ester or amide derivative of bromoacetic acid.
The esters or amide derivatives of bromoacetic acid were either
commercially available or formed in one step via the reaction of
bromoacetyl bromide with the appropriate alcohol or amine.21 An
advantage of this route is that a wide range of ester and amide side
chains can be prepared easily. For ionic liquids with anions other
than bromide, a metathesis reaction was employed to introduce the
counter ion of choice (Scheme 1). Metathesis of the halide anion to
BF42, PF62, NTf22 and N(CN)22 proceeded in good to excellent
yield. BF42 ionic liquids were prepared by counter-ion exchange
with NaBF4 in acetonitrile. Removal of the solvent gave IL
contaminated with trace NaBF4 as shown by 19F NMR. Clean
samples could be isolated after a simple work-up. Compound 9h
was prepared by counter-ion exchange with KPF6 in acetonitrile.
PF62 and NTf22 based ionic liquids (except 9h) were prepared by
mixing an aqueous solution of the bromide salt with KPF6 or
LiNTf2, respectively. The hydrophobic IL phase was separated,
washed and residual water removed under high vacuum to give
pure samples. N(CN)22 ionic liquids were prepared by counter-ion
exchange with NaN(CN)2 in acetonitrile analogously to the BF42
ionic liquid examples.22
Imidazolium salts with ester containing side chains were
generally found to be liquids a room temperature; 21 of the 23 ester
containing compounds proved to be liquids at room temperature,
though compound 8a and all ILs with the bromide counter ion were
viscous at room temperature. ILs with amide containing side chains
were less likely to be room temperature ionic liquids; 6 of the 12
examples prepared were solids at room temperature. The secondary
amide derivatives 7h and 9h were solids, presumably due to
increased intermolecular forces resulting from H-bonding. Imida-
zolium salts with N,N-diethyl amide side chains (compounds 7j, 9j
and 10j) were solids, while N-butyl-N-methyl amides (compounds
7i, 8i, 10i, 11i) were liquids at room temperature.
There are two main features of the N-butyl-N-methyl amides (7i–
11i) which affect their macroscopic properties. Firstly, the
unsymmetrical environment around the nitrogen of the amide (cf.
with solid N,N-diethyl amide examples 7j, 9j and 10j), as symmetry
has previously been reported as important regarding melting
point.1,23 Secondly, the N-butyl-N-methyl amides (7i–11i) prepared
exist as a 1 : 1.3 mixture of rotomers around the amide bond and it
Scheme 1 IL synthesis [compounds in parentheses are solids at room
temperature].
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is proposed that this isomeric mixture leads to a depression of the
melting point.24
All the ionic liquids prepared in this paper have melting points
below 100 °C, a benchmark which has been set to determine their
classification as ILs.8
All PF6 and NTf2 ILs containing an ester or amide in the side
chain were hydrophobic except for the secondary amide derivative
9h. The introduction of the polar functional group did not
significantly affect the water solubility of the IL. The use of PF6
ionic liquids outside of the research laboratory has been questioned
due to their propensity to evolve HF if not stored and handled
carefully.5c The authors note that for the ionic liquids presented
within, HF formation would lead to decomposition. The PF6 ILs
were prepared to study their properties however their suitability as
industrial chemicals seems limited.
Biodegradation testing data
Two samples (7b and 8b) were evaluated in a commercial
laboratory25 using a modified Sturm test (OECD 301B). In this test,
the chemical being evaluated is added to aerobic aqueous medium
inoculated with wastewater micro organisms and the evolution of
CO2 is measured for a defined period and reported as a percentage
of the theoretical maximum. The Organisation for Economic
Cooperation and Development (OECD) has approved this modified
Sturm test as one means of assessing biodegradability.26 Com-
pounds which evolve more than 60% of the total CO2 are
considered to be a pass (OECD 301B). This test was applied to two
dialkylimidazoles with ester containing side chains (compounds 7b
and 8b) and bmimPF6. All three examples appeared to be relatively
close to the pass level (7b = 48%, 8b = 59% and bmimPF6 =
60%). After these preliminary results a more comprehensive
biodegradation study was initiated.
A larger panel of ionic liquids with functionalised side chains
were evaluated using the ‘Closed Bottle Test’ (OECD 301D).27 In
this test the IL was added to an aerobic aqueous medium inoculated
with wastewater micro organisms and the depletion of dissolved
molecular oxygen was measured for a defined period of time and
reported as a percentage of the theoretical maximum. Duplicate
bottles of each series were analysed at the start of the test for
dissolved oxygen and the remaining bottles were incubated at 20
°C±1 °C in the dark. Bottles of all series were withdrawn in
duplicate for dissolved oxygen analysis over the 28-day incubation
period. A control with inoculum, but without test chemicals was run
in parallel for the determination of oxygen blanks. Sodium n-
dodecyl sulfate (SDS) was used as reference substance. Com-
pounds which reached a biodegradation level higher than 60% are
referred to as readily biodegradable. Readily biodegradable has
been defined as “an arbitrary classification of chemicals which have
passed certain specified screening tests for ultimate biodegrad-
ability; the conditions in these tests are so stringent – relatively low
density of non-acclimatized bacteria, relatively short duration,
absence of other compounds – that such chemicals will rapidly and
completely biodegrade in aquatic environments under aerobic
conditions”.11
The data showed significant differences between the bio-
degradability of the ionic liquids incorporating an ester group and
those containing an amide linker in the side chain. ILs incorporating
different alkyl esters (from methyl to octyl) in the side chain
presented similar biodegradation profiles (Fig. 1).
It appears that the biodegradation increased slightly with
increasing alkyl chain length for the lowest alkyl esters and later
remained relatively constant (Fig. 2). Regarding the structure of
ionic liquids containing an ester group in the chain side, it seems
reasonable that the biodegradation of these molecules may be
initiated by enzymatic cleavage of the ester bond leading to the
separation of the imidazolium fragment and the corresponding
primary alcohol that can readily be metabolized via the pathway of
fatty acid b-oxidation.17
No evidence for some extent of ultimate biodegradation was
detected for ILs containing an amide linker in the side chain (Fig.
3).
The two most widely used ionic liquids in academia and industry
are based on the 1-n-butyl-3-methylimidazolium core. i.e.
bmimBF4 and bmimPF6. These ILs, with bmimBr, were also tested
for biodegradation by the ‘Closed Bottle Test’ (OECD 301D).
BmimBF4 and bmim PF6 were found to show no biodegradation
(0%) in this test. BmimBr was found to have negligible biodegrada-
tion as measured by the Closed Bottle Test (1%). Comparison of
compounds 7a–j and bmimBr shows that the incorporation of the
ester functional group has greatly improved the biodegradation
properties of the IL. A more detailed study of counter-ion effect on
biodegradation is in progress.
The results obtained from the Closed Bottle Test differed from
those obtained using the modified Sturm test, with the latter
Fig. 1 Biodegradation curves of the ionic liquids containing an ester group
in the cation side chain (3-methyl-1-(alkyloxymethylcarbonyl)-imidazo-
lium bromides): Me (5), Et (:), Pr (!), Bu (< ), Pent (+), Hex (3), Oct
(*); reference substance: SDS (-).
Fig. 2 Biodegradation (28-day period) of 3-methyl-1-(alkyloxycarbo-
nylmethyl)imidazolium bromides as a function of the number of carbon
atoms of the alkyl chain.
Fig. 3 Biodegradation curves of ionic liquids incorporating an amide
group in the cation side chain: N(Et2) (5), N(BuH) (:), N(BuMe) (!);
reference substance: SDS (-).
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indicating higher levels of biodegradation. Such differences may be
related to the inoculum that was used. Biodegradation is intimately
bound up with bacterial growth, nutrition and metabolism, and
factors which affect these bacterial functions will also affect the
biodegradability assessments. The nature and quantity of the
inoculum play an important role in biodegradability assessment; the
inoculum is probably the biggest single factor in the success of the
batch test. Although the Closed Bottle and modified Sturm test have
a number of similarities, the inoculum cell densities in these tests
methods vary considerably (Closed Bottle Test; 101–103 cells
mL21, modified Sturm test; 104–106cells mL21). The bacterial cell
density in the medium determines, to a large extent, the length of
the lag period and also whether sufficient test substance is degraded
within the duration of the test. If the number of cells capable of
degrading the test substance is relatively high, the density will soon
reach a value which makes a significant reduction in the
concentration of the substance. However, when the initial cell
density is relatively low, the lag period before a significant density
is reached may be longer than the period of the test (28 days). Thus,
the large differences found in the extent of ultimate biodegradation
applying these two biodegradation methods could be reasonably
attributed to significant variability in cell density.
The biodegradation data should be interpreted with caution
taking into account the features both of the biodegradation test
applied as well of the chemicals studied. Screening methods have
been used in many studies on the biodegradability of quaternary
ammonium compounds, namely surfactants such as alkyltrimethyl
ammonium salts and benzylalkyldimethyl ammonium salts.28,29 It
has been found that degradation rates of these compounds in
screening methods significantly underestimated the rate and the
extent of degradation occurring in natural environmental sys-
tems.30,31 Since imidazolium compounds are similarly charged
ammonium ion-species similar results would be expected.
The toxicity of the ionic liquids may also have an negative
impact on their biodegradation. Many quaternary ammonium salts
are potential biocides and could inhibit growth of micro organisms
capable of degrading quaternary ammonium salts.32–35 Ranke et
al.36 recently conducted the first comprehensive study on the
biological effects of dialkylimidazolium ionic liquids. Cytoxic
effects of IL were determined against two mammalian cell lines
(the promyeloctic leukaemia rat cell line IPC-18 and the rat glioma
cell line C6) while acute toxicity was measured using a luminescent
bacteria (Vibrio fischeri) assay. In general the toxicity of the ILs
was found to be some orders of magnitude lower than that of the
conventional solvents such as acetone, acetonitrile, methanol and
methyl tert-butyl ether. The length of the alkyl chains was found to
influence the toxicity of the dialkylimidazolium ILs, with longer
chain lengths proving to be more toxic. A search of the literature
shows that the biological properties of these biocides is related to
their long alkyl chain length.37,38
The anti-microbial activity of a series of 3-alkoxymethyl-
1-methylimidazolium ionic liquids (13, R = C3H7–C16H33, X =
Cl, BF4, PF6) has also been investigated.37 ILs with shorter alkoxy
substituents lacked activity against cocci, rods and fungi, while
those with longer alkoxy chains ( > 10 carbon atoms) proved to be
very active. These findings have implications for the use of such IL
as media for biotransformations as well as their degradation by
micro organisms. A study of soft antimicrobials including 1-[(n-
dodecanoyloxy)methyl]-3-methylimidazolium chloride (14) by
Bodor et al. showed that the long chain ester derivatives of methyl
imidazole (including 14) show effective antimicrobial activity at
ppm concentrations.39 Similarly, other alkyl substituted imidazo-
lium compounds (e.g. 15) have also been found to possess
biological activity.40
Therefore, the biodegradation results found could be related to
the inhibitory effects of the quaternary ammonium salts on the
bacterial populations. In light of these results, further investigations
on biodegradability and potential toxicity of ionic liquids should be
carried out.
Conclusions
ILs containing an ester in the side-chain were generally found to be
liquids at room temperature, independent of the counter-ion. The
amide derivatives were solids at room temperature except for the N-
butyl-N-methyl series. NTf2 and PF6 ILs containing an ester in the
side chain exhibited the same hydrophobic character as bmimNTf2
and bmimPF6.
The Bmim derived ILs and examples containing an amide in the
side chain were found to show poor to negligible biodegradation as
measured by the Closed Bottle Test (OECD 301D). The incorpora-
tion of an ester in the side chain resulted in a significant increase in
biodegradation. Esters of type 7 with an alkyl chain length of 44
proved to be the most biodegradable. It is postulated that this
improved biodegradation is due in part to an enzymatic hydrolysis
step which initiates a pathway to further breakdown products.
Significant enhancement in the biodegradation of methylimidazo-
lium ILs has been achieved. The factors which improved the
biodegradation of surfactants have successfully been applied to
ionic liquids.
Experimental
Methyl bromoacetate, ethyl bromoacetate, propyl bromoacetate
were purchased from Aldrich and used without further purification.
Butyl bromoacetate, pentyl bromoacetate, hexyl bromoacetate,
octyl bromoacetate, N,N-diethyl-2-bromo-acetamide, N-butyl-
2-bromoacetamide and N-butyl-N-methyl-2-bromoacetamide were
prepared as described below, and purified by distillation. Ethyl
chloroacetate was purchased from Fluka and used without further
purification. 1-Methylimidazole (99%, Aldrich) was distilled
before use to remove impurities detrimental to all ILs prepared. All
organic solvents were dried and distilled before use. ILs were
washed with distilled water. 3-Methyl-1-(methoxycarbonylmethy-
l)imidazolium bromide (3a) was prepared according to the
literature [mp = 131–133 °C].19 1-n-Butyl-3-methylimidazolium
BF4, PF6 and NTf2 were prepared according to the literature. All
NMR spectra of ILs were recorded in CD3CN (Aldrich 15,180–7,
99.8 atom %D) on a Bruker Avance DPX 300 spectrometer. 1H and
13C NMR spectra were recorded at 300 MHz and 75.4 MHz
respectively. NMR spectra of the ester and amide derivatives of
bromoacetic were recorded in CDCl3. Melting points are un-
corrected. All room temperature ionic liquids were placed in the
fridge (2 °C) and freezer (218 °C) to further evaluate their melting
points. Unless indicated in the experimental data below (see 8g and
9g) all the room temperature ionic liquids did not crystallise at 218
°C. However, the viscosity of the ionic liquids at this temperature
was significantly increased. A study of glass transition tem-
peratures was not attempted with these materials. Determination of
the physical properties of the ionic liquids prepared is still in
progress (e.g. solubility, thermal stability, viscosity, density and
stability to hydrolysis41) and will be reported in due course.
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3-Methyl-1-(ethoxycarbonylmethyl)imidazolium bromide
(7b)
To a stirred solution of 1-methylimidazole (4.1 g, 4.0 mL, 50 mmol)
in THF (50 mL) at 25 °C under a nitrogen atmosphere was added
dropwise ethyl bromoacetate (10.0 g, 6.7 mL, 60 mmol). The
reaction mixture was stirred vigorously at 25 °C for 1 h, then at rt
for 3 h. The THF top phase was decanted and the IL washed with
diethyl ether (3 3 10 mL), then residual solvent removed in vacuo.
The product was dried at 60 °C at 0.01 mmHg for 72 h to give a
clear viscous hygroscopic oil in 98% yield (12.2 g, 49 mmol). 1H
NMR (300 MHz, CD3CN) 9.38 (s, 1H), 7.64 (s, 1H), 7.51 (s, 1H),
5.30 (s, 2H), 4.23 (q, J = 7.0 Hz, 2H), 3.93 (s, 3H), 1.25 (t, J = 7.0
Hz, 3H). 13C NMR (75 MHz) d 167.80, 138.72, 124.82, 124.10,
63.23, 51.06, 37.40, 14.63. MS (ESI): m/z, 169.1 [M2Br2]+; MS
(ESI): m/z, 79 and 81 [Br2].
3-Methyl-1-(propoxycarbonylmethyl)imidazolium bromide
(7c)
This compound was prepared analogously to 7b using 1-methylimi-
dazole (2.11 g, 2.05 mL, 25 mmol) and propyl bromoacetate (5.46
g, 3.90 mL, 30 mmol) to give a clear viscous hygroscopic oil in 96%
yield (6.31 g, 24 mmol). 1H NMR (300 MHz, CD3CN) d 9.57 (s,
1H), 7.78 (s, 1H), 7.63 (s, 1H), 5.42 (s, 2H), 4.10 (q, J = 7.0 Hz,
2H), 3.94 (s, 3H), 1.62 (tq, J = 7.0, 7.0 Hz, 2H), 0.89 (t, J = 7.0
Hz, 3H). 13C (75 MHz) d 167.93, 138.89, 124.81, 124.40, 68.73,
51.08, 37.40, 22.68, 10.75. MS (ESI): m/z, 183.1 [M2Br2]+; MS
(ESI): m/z, 79 and 81 [Br2].
3-Methyl-1-(butoxycarbonylmethyl)imidazolium bromide
(7d)
This compound was prepared analogously to 7b using 1-methylimi-
dazole (3.86 g, 3.75 mL, 47 mmol) in diethyl ether (50 mL) and
butyl bromoacetate (11.0 g, 56.4 mmol) to give a clear viscous
hygroscopic oil in 98% yield (12.75 g, 47 mmol). 1H NMR (300
MHz, CD3CN) d 9.44 (s, 1H), 7.66 (s, 1H), 7.53 (s, 1H), 5.33 (s,
2H), 4.18 (t, J = 7.0 Hz, 2H), 3.93 (s, 3H), 1.62 (tt, J = 7.5, 7.5 Hz,
2H), 1.38 (tt, J = 7.5, 7.5 Hz, 3H), 0.92 (t, J = 7.0 Hz, 3H). 13C (75
MHz) d 167.58, 138.76, 124.66, 124.23, 66.94, 66.20, 50.90, 37.16,
31.15, 19.63, 13.89. MS (ESI): m/z, 197.2 [M2Br2]+; MS (ESI):
m/z, 79 and 81 [Br2].
3-Methyl-1-(pentoxycarbonylmethyl)imidazolium bromide
(7e)
This compound was prepared analogously to 7b using 1-methylimi-
dazole (4.93 g, 4.78 mL, 60 mmol) in diethyl ether (50 mL) and
pentyl bromoacetate (15.0 g, 71.8 mmol) to give a clear viscous
hygroscopic oil in 97% yield (16.98 g, 58 mmol). 1H NMR (300
MHz, CD3CN) d 9.49 (s, 1H), 7.69 (s, 1H), 7.55 (s, 1H), 5.36 (s,
2H), 4.16 (t, J = 7.0 Hz, 2H), 3.94 (s, 3H), 1.61 (tt, J = 7.5, 7.5 Hz,
2H), 1.38–1.28 (m, 4H), 0.89 (t, J = 7.0 Hz, 3H). 13C (75 MHz) d
167.56, 138.75, 124.62, 124.18, 67.16, 50.87, 37.13, 28.76, 28.48,
22.84, 14.17. MS (ESI): m/z, 211.1 [M2Br2]+; MS (ESI): m/z, 79
and 81 [Br2].
3-Methyl-1-(hexoxycarbonylmethyl)imidazolium bromide
(7f)
To a stirred solution of 1-methylimidazole (2.11 g, 2.05 mL, 25
mmol) in diethyl ether (25 mL) at 25 °C under a nitrogen
atmosphere was added dropwise hexyl bromoacetate (6.70 g, 5.31
mL, 30 mmol). The reaction mixture was stirred vigorously at 25
°C for 1 h, then at rt for 3 h. The diethyl ether top phase was
decanted and the IL washed with diethyl ether (3 3 10 mL) then
residual solvent removed in vacuo. The product was dried at 60 °C
at 0.01 mmHg for 72 h to give a clear viscous hygroscopic oil in
92% yield (7.01 g, 23.0 mmol). 1H NMR (300 MHz, CD3CN) d
9.49 (s, 1H), 7.69 (s, 1H), 7.56 (s, 1H), 5.36 (s, 2H), 4.15 (t, J = 7.0
Hz, 2H), 3.93 (s, 3H), 1.67–1.57 (m, 2H), 1.40–1.25 (m, 6H), 0.87
(t, J = 7.0 Hz, 3H). 13C (75 MHz) d 167.95, 139.03, 124.95,
124.54, 67.51, 51.20, 37.50, 32.32, 29.36, 26.35, 23.48, 14.60. MS
(ESI): m/z, 225.2 [M2Br2]+; MS (ESI): m/z, 79 and 81 [Br2].
3-Methyl-1-(octoxycarbonylmethyl)imidazolium bromide
(7g)
This compound was prepared analogously to 7f using 1-methylimi-
dazole (0.84 g, 0.82 mL, 10.3 mmol) and octyl bromoacetate
(3.01g, 12.0 mmol) to give a clear viscous hygroscopic oil in 95%
yield (3.26 g, 9.8 mmol). 1H NMR (300 MHz, CD3CN) d 9.41 (s,
1H), 7.64 (s, 1H), 7.53 (s, 1H), 5.32 (s, 2H), 4.17 (t, J = 7.0 Hz,
2H). 3.94 (s, 3H), 1.70–1.60 (m, 2H), 1.40–1.20 (m, 10H), 0.88 (t,
J = 7.0 Hz, 3H). 13C (75 MHz) d 167.97, 139.08, 125.00, 124.59,
67.58, 51.23, 37.52, 32.84, 30.23, 30.18, 29.48, 26.75, 23.68, 14.73.
MS (ESI): m/z, 253.3 [M2Br2]+; MS (ESI): m/z, 79 and 81
[Br2].
3-Methyl-1-(N-butylcarbamoylmethyl)imidazolium
bromide (7h)
This compound was prepared analogously to 7f using 1-methylimi-
dazole (0.42 g, 0.41 mL, 5.0 mmol) and N-butyl-2-bromoacetamide
(1.16 g, 6.0 mmol) to give an oil in 94% yield (1.30 g, 4.7 mmol).
The oil slowly crystallised at room temperature. 1H NMR (300
MHz, CD3CN) d 9.11 (s, 1H), 8.39 (bs, 1H, NH), 7.56 (s, 1H), 7.45
(s, 1H), 5.14 (s, 2H), 3.90 (s, 3H), 3.15 (q, J = 7.0 Hz, 2H),
1.52–1.40 (m, 2H), 1.40–1.37 (m, 2H), 0.87 (t, J = 7.0 Hz, 3H). 13C
NMR (75 MHz) d 166.12, 138.89, 124.99, 124.58, 52.70, 40.48,
37.62, 32.55, 21.28, 14.57. MS (ESI): m/z, 196.1 [M2Br2]+; MS
(ESI): m/z, 79 and 81 [Br2].
3-Methyl-1-(N-butyl-N-methylcarbamoylmethyl)-
imidazolium bromide (7i)
To a stirred solution of 1-methylimidazole (821 mg, 0.80 mL, 10
mmol) in THF (15 mL) at 25 °C under a nitrogen atmosphere was
added dropwise N-butyl-N-methyl-2-bromoacetamide (2.50 g, 12
mmol, 1 : 1.3 mixture of isomers) in THF (5 mL). The reaction
mixture was stirred vigorously at 25 °C for 1 h, then at rt for 48 h.
The THF top phase was decanted and the IL washed with THF (2
3 5 mL), then residual solvent removed in vacuo. The product was
dried at 60 °C at 0.01 mmHg for 72 h to give a clear viscous
hygroscopic oil in 95% yield (2.76 g, 9.51 mmol). * denotes both
isomers. 1H NMR (300 MHz, CD3CN) d 8.78 (s, 1H, minor), 8.74
(s, 1H, major), 7.43–7.35 (m, 2H*), 5.22 (s, 2H, major), 5.19 (s, 2H,
minor), 3.90 (s, 3H*), 3.37 (t, J = 7.0 Hz, 2H, major), 3.30 (t, J =
7.0 Hz, 2H, minor), 3.02 (s, 3H, major), 2.92 (s, 3H, minor),
1.70–1.25 (m, 4H*), 0.99 (t, J = 7.0 Hz, 3H, minor), 0.93 (t, J =
7.0 Hz, 3H, major). 13C (75 MHz) d 165.85 (major), 165.53
(minor), 138.89 (minor), 138.72 (major), 125.01 (minor), 124.91
(major), 123.75 (minor), 123.72 (major), 51.70 (major), 51.33
(minor), 49.64 (minor), 48.53 (major), 37.19*, 34.96 (major), 34.24
(minor), 30.86 (minor), 29.94 (major), 20.69 (minor), 20.58
(major), 14.25*. MS (ESI): m/z, 210.2 [M2Br2]+; MS (ESI): m/z,
79 and 81 [Br2].
3-Methyl-1-(N,N-diethylcarbamoylmethyl)imidazolium
bromide (7j)
This compound was prepared analogously to 7b using 1-methylimi-
dazole (1.05 g, 1.02 mL, 12.8 mmol) and N,N-diethyl-2-bromoace-
tamide (2.98 g, 15.4 mmol) to give a crystalline solid in 99% yield
(3.51 g, 12.7 mmol). mp = 66–68 °C; 1H NMR (300 MHz,
CD3CN) d 9.27 (s, 1H), 7.60 (s, 1H), 7.47 (s, 1H), 5.44 (s, 2H), 3.91
(s, 3H), 3.37 (q, J = 7.0 Hz, 2H), 3.34 (q, J = 7.0 Hz, 2H), 1.24 (t,
J = 7.0 Hz, 3H), 1.06 (t, J = 7.0 Hz, 3H). 13C (75 MHz) d 165.17,
139.25, 125.54, 124.14, 51.80, 42.60, 41.97, 37.55, 14.86, 13.67.
MS (ESI): m/z, 196.1 [M2Br2]+; MS (ESI): m/z, 79 and 81
[Br2].
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3-Methyl-1-(methoxycarbonylmethyl)imidazolium BF4
(8a)
A dry flask was charged with 3-methyl-1-(methoxycarbonylmethy-
l)imidazolium bromide (7a) (702 mg, 3.0 mmol) and acetonitrile (2
mL) under a nitrogen atmosphere. NaBF4 (362 mg, 3.3 mmol) was
added in one portion and the suspension was stirred vigorously for
4 days at rt. The fine white precipitate was filtered quickly in air and
washed with dry acetonitrile (2 3 1 mL). The filtrate and washings
were combined, solvent removed by rotary evaporation then in
vacuo. The product was dried at 60 °C at 0.01 mmHg for 72 h to
give a clear viscous hygroscopic oil in 96% yield (0.70 g, 2.9
mmol). 1H NMR (300 MHz, CD3CN) d 8.58 (s, 1H), 7.40 (s, 2H),
5.02 (s, 2H), 3.89 (s, 3H), 3.78 (s, 3H). 13C (75 MHz) d 168.33,
138.75, 125.15, 125.00, 54.33, 51.18, 37.63. 19F (254 MHz) d
2151.6 (BF42). MS (ESI): m/z, 155.1 [M2BF42]+; MS (ESI): m/z,
87.0 [BF42].
3-Methyl-1-(ethoxycarbonylmethyl)imidazolium BF4 (8b)
This compound was prepared analogously to 8a using 3-methyl-
1-(ethoxycarbonylmethyl)imidazolium bromide 7b (1.79 g, 6.3
mmol) and NaBF4 (0.69 g, 6.3 mmol) to give a clear viscous
hygroscopic oil in 92% yield (1.51 g, 5.9 mmol). 1H NMR (300
MHz, CD3CN) d 8.66 (s, 1H), 7.44 (s, 1H), 7.40 (s, 1H), 5.30 (s,
2H), 4.25 (q, J = 7.0 Hz, 2H), 3.89 (s, 3H), 1.29 (t, J = 7.0 Hz, 3H).
13C (75 MHz) d 167.83, 138.80, 125.16, 124.93, 63.90, 51.31,
37.64, 14.83. 19F (254 MHz) d 2151.6 (BF42). MS (ESI): m/z,
169.1 [M2BF42]+; MS (ESI): m/z, 87.0 [BF42].
3-Methyl-1-(propoxycarbonylmethyl)imidazolium BF4 (8c)
This compound was prepared analogously to 8a using 3-methyl-
1-(propoxycarbonylmethyl)imidazolium bromide 7c (722 mg, 2.8
mmol) and NaBF4 (333 mg, 3.0 mmol) to give a clear viscous
hygroscopic oil in 98% yield (727 mg, 2.7 mmol). 1H NMR (300
MHz, CD3CN) d 8.55 (s, 1H), 7.41 (s, 2H), 7.40 (s, 1H), 5.00 (s,
2H), 4.17 (t, J = 7.0 Hz, 2H), 3.88 (s, 3H), 1.70 (qt, J = 7.0, 7.0
Hz, 2H), 0.95 (t, J = 7.0 Hz, 3H). 13C (75 MHz) d 167.90, 138.76,
125.15, 124.9, 69.24, 51.22, 37.58, 23.00, 10.96. 19F (254 MHz) d
2151.5 (BF42). MS (ESI): m/z, 183.1 [M2BF42]+; MS (ESI): m/z,
87.0 [BF42].
3-Methyl-1-(hexoxycarbonylmethyl)imidazolium BF4 (8f)
This compound was prepared analogously to 8a using 3-methyl-
1-(hexoxycarbonylmethyl)imidazolium bromide 7f (758 mg, 2.25
mmol) and NaBF4 (247 mg, 2.50 mmol) to give a clear viscous
hygroscopic oil in 90% yield (630 mg, 2.0 mmol). 1H NMR (300
MHz, CD3CN) d 8.63 (s, 1H), 7.43 (s, 2H), 7.40 (s, 1H), 5.02 (s,
2H), 4.19 (t, J = 7.0 Hz, 2H), 3.88 (s, 3H), 1.70–1.60 (m, 2H),
1.42–1.28 (m, 6H), 0.91 (t, J = 7.0 Hz, 3H). 13C (75 MHz) d
167.85, 138.76, 125.17, 124.94, 67.87, 51.30, 37.64, 32.55, 29.56,
26.58, 23.72, 14.77. 19F (254 MHz) d2151(BF42). MS (ESI): m/z,
225.2 [M2BF42]+ MS (ESI): m/z, 87.0 [BF42].
3-Methyl-1-(octoxycarbonylmethyl)imidazolium BF4 (8g)
This compound was prepared analogously to 8a using 3-methyl-
1-(octoxycarbonylmethyl)imidazolium bromide 7g (350 mg, 1.05
mmol) and NaBF4 (127 mg, 1.16 mmol) to give a clear viscous
hygroscopic oil in 97 % yield (346 mg, 1.02 mmol). The oil
crystallised in the freezer at 218 °C. 1H NMR (300 MHz, CD3CN)
d 8.50 (s, 1H), 7.40 (s, 2H), 7.38 (s, 1H), 4.98 (s, 2H), 4.19 (t, J =
7.0 Hz, 2H), 3.88 (s, 3H), 1.70–1.60 (m, 2H), 1.42–1.25 (m, 10H),
0.91 (t, J = 7.0 Hz, 3H). 13C (75 MHz) d 167.87, 138.79, 125.16,
124.95, 67.85, 51.25, 37.60, 33.00, 30.38, 30.32, 29.59, 26.89,
23.83, 14.88. 19F (254 MHz) d 2151.4 (BF42). MS (ESI): m/z,
253.3 [M2BF42]+; MS (ESI): m/z, 87.0 [BF42].
3-Methyl-1-(N-butylcarbamoylmethyl)imidazolium BF4
(8h)
This compound was prepared analogously to 8a using 3-methyl-
1-(N-butylcarbamoylmethyl)imidazolium bromide 7h (128 mg,
0.45 mmol) and NaBF4 (50 mg, 0.50 mmol) in acetonitrile (1 mL)
to give a clear viscous hygroscopic oil in 86% yield (110 mg, 0.39
mmol). 1H NMR (300 MHz, CD3CN) d 8.55 (s, 1H), 7.39 (s, 1H),
7.35 (s, 1H), 7.05 (bs, 1H, NH), 4.85 (s, 2H), 3.86 (s, 3H), 3.20 (q,
J = 7.0 Hz, 2H), 1.55–1.40 (tt, J = 7.0, 7.0 Hz, 2H), 1.40–1.28 (qt,
J = 7.0, 7.0 Hz, 2H), 0.92 (t, J = 7.0 Hz, 3H). 13C (75 MHz) d
165.73, 138.65, 125.10, 124.59, 52.39, 20.54, 37.50, 32.52, 21.11,
14.45. 19F (254 MHz) d 2151.7 (BF42). MS (ESI): m/z, 196.1
[M2BF42]+; MS (ESI): m/z, 87.0 [BF42].
3-Methyl-1-(N-butyl-N-methylcarbamoylmethyl)-
imidazolium BF4 (8i)
This compound was prepared analogously to 8a using 3-methyl-
1-(N-butyl-N-methylcarbamoylmethyl)imidazolium bromide 7i
(256 mg, 0.88 mmol, 1 : 1.3 mixture of isomers) and NaBF4 (107
mg, 0.97 mmol) to give a clear viscous hygroscopic oil in 98% yield
(256 mg, 0.86 mmol, 1 : 1.3 mixture of isomers). * denotes both
isomers. 1H NMR (300 MHz, CD3CN) d 8.46 (s, 1H, minor), 8.44
(s, 1H, major), 7.40–7.30 (m, 2H*), 5.08 (s, 2H, minor), 5.05 (s, 2H,
major), 3.88 (s, 3H*), 3.37 (t, J = 7.0 Hz, 2H, major), 3.28 (t, J =
7.0 Hz, 2H, minor), 3.00 (s, 3H, major), 2.92 (s, 3H, minor),
1.70–1.25 (m, 4H*), 0.99 (t, J = 7.0 Hz, 3H, minor), 0.93 (t, J =
7.0 Hz, 3H, major). 13C (75 MHz) d 166.05 (major), 165.79
(minor), 139.14 (minor), 139.04 (major), 125.48 (minor), 125.44
(major), 124.43*, 121.42* (q, J = 320 Hz, CF3), 51.76 (major),
51.51 (minor), 50.01 (minor), 49.15 (major), 37.41*, 35.07 (major),
34.65 (minor), 31.21 (minor), 30.35 (major), 21.10 (minor), 21.09
(major), 14.74 (major), 14.69 (minor). 19F (254 MHz) d 2152.10
(BF42). MS (ESI): m/z, 210.2 [M2BF42]+; MS (ESI): m/z, 87.0
[BF42].
3-Methyl-1-(N,N-diethylcarbamoylmethyl)-
imidazolium BF4 (8j)
This compound was prepared analogously to 8a using 3-methyl-
1-(N,N-diethylcarbamoylmethyl)imidazolium bromide 7j (552 mg,
2.0 mmol) and NaBF4 (242 mg, 2.2 mmol) to give a clear viscous
hygroscopic oil in 92% yield (520 mg, 1.84 mmol). 1H NMR (300
MHz, CD3CN) d 8.55 (s, 1H), 7.38 (s, 2H), 5.10 (s, 2H), 3.83 (s,
3H), 3.30 (m, 4H), 1.19 (t, J = 7.0 Hz), 1.07 (t, J = 7.0 Hz).13C (75
MHz) d 163.72, 137.68, 124.10, 122.95, 50.22, 41.12, 40.58,,
36.01, 13.25, 12.21. 19F (254 MHz) d2150.8 (BF42). MS (ESI): m/
z, 196.1 [M2BF42]+; MS (ESI): m/z, 87.0 [BF42].
3-Methyl-1-(methoxycarbonylmethyl)imidazolium PF6
(9a)
A flask was charged with 3-methyl-1-(methoxycarbonylmethyl)i-
midazolium bromide 7a (702 mg, 3.0 mmol) and distilled water (2
mL). KPF6 (607 mg, 3.3 mmol) in distilled water (1 mL) was added
in one portion and the suspension was stirred vigorously for 4 h at
rt. The top aqueous layer was removed, the IL washed with water
(3 3 1 mL) then the solvent removed in vacuo. The product was
dried at 60 °C at 0.01 mmHg for 72 h to give a crystalline solid in
67% yield (0.61 g, 2.0 mmol). mp = 76–78 °C; 1H NMR (300
MHz, CD3CN) d 8.49 (s, 1H), 7.39 (s, 2H), 4.99 (s, 2H), 3.88 (s,
3H), 3.79 (s, 3H). 13C (75 MHz) d 168.32, 138.67, 125.14, 125.02,
54.35, 51.18, 37.64; 19F (254 MHz) d 273.0 (d, JP–F = 707 Hz,
PF62); MS (ESI): m/z, 155.1 [M2PF62]+; MS (ESI): m/z, 144.9
[PF62].
3-Methyl-1-(ethoxycarbonylmethyl)imidazolium PF6 (9b)
This compound was prepared analogously to 9a using 3-methyl-
1-(ethoxycarbonylmethyl)imidazolium bromide 7b (0.55 g, 2.2
mmol) and KPF6 (0.41 g, 2.2 mmol) to give a clear viscous oil in
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68% yield (0.47 g, 1.5 mmol). 1H NMR (300 MHz, CD3CN) d 8.47
(s, 1H), 7.39 (s, 2H), 4.97 (s, 2H), 4.26 (q, J = 7.0 Hz, 2H), 3.88
(s, 3H), 1.29 (t, J = 7.0 Hz, 3H). 13C (75 MHz) d 167.80, 138.65,
125.18, 125.00, 63.98, 51.30, 37.63, 14.84. 19F (254 MHz) d272.5
(d, JP–F = 707 Hz, PF62). MS (ESI): m/z, 169.1 [M2PF62]+; MS
(ESI): m/z, 144.9 [PF62].
3-Methyl-1-(propoxycarbonylmethyl)imidazolium PF6 (9c)
This compound was prepared analogously to 9a using 3-methyl-
1-(propoxycarbonylmethyl)imidazolium bromide 7c (0.60 g, 2.3
mmol) and KPF6 (464 mg, 2.5 mmol) to give a clear viscous oil in
78% yield (585 mg, 1.8 mmol). 1H NMR (300 MHz, CD3CN) d
8.47 (s, 1H), 7.39 (s, 2H), 4.98 (s, 2H), 4.17 (t, J = 7.0 Hz, 2H),
3.88 (s, 3H), 1.69 (qt, J = 7.0, 7.0 Hz, 2H), 0.95 (t, J = 7.0 Hz, 3H);
13C (75 MHz) d 167.84, 138.65, 125.18, 124.99, 69.32, 51.28,
37.64, 23.03, 10.98; 19F (254 MHz) d 272.7 (d, JP–F = 707 Hz,
PF62); MS (ESI): m/z, 183.1 [M2PF62]+; MS (ESI): m/z, 144.9
[PF62].
3-Methyl-1-(hexoxycarbonylmethyl)imidazolium PF6 (9d)
This compound was prepared analogously to 9a using 3-methyl-
1-(hexoxycarbonylmethyl)imidazolium bromide 7d (762 mg, 2.3
mmol) and KPF6 (458 mg, 2.5 mmol) to give a clear viscous oil in
89% yield (0.76 g, 2.1 mmol). 1H NMR (300 MHz, CD3CN) d 8.49
(s, 1H), 7.39 (s, 2H), 4.98 (s, 2H), 4.20 (t, J = 7.0 Hz, 2H), 3.88 (s,
3H), 1.70–1.60 (m, 2H), 1.40–1.30 (m, 6H), 0.90 (t, J = 7.0 Hz,
3H). 13C (75 MHz) d 167.78, 138.62, 125.17, 124.97, 67.89, 51.28,
37.62, 32.54, 29.56, 26.57, 23.71, 14.77. 19F (254 MHz) d 271.94
(d, JP–F = 707 Hz, PF62). MS (ESI): m/z, 225.2 [M2PF62]+ MS
(ESI): m/z, 144.9 [PF62].
3-Methyl-1-(octoxycarbonylmethyl)imidazolium PF6 (9g)
This compound was prepared analogously to 9a using 3-methyl-
1-(octoxycarbonylmethyl)imidazolium bromide 7g (528 mg, 1.58
mmol) and KPF6 (321 mg, 1.74 mmol) to give a colourless oil in
81% yield (508 mg, 1.27 mmol). The oil crystallised in the fridge
at 2 °C. 1H NMR (300 MHz, CD3CN) d 8.46 (s, 1H), 7.39 (s, 2H),
4.96 (s, 2H), 4.19 (t, J = 7.0 Hz, 2H), 3.88 (s, 3H), 1.72–1.60 (m,
2H), 1.42–1.25 (m, 10H), 0.90 (t, J = 7.0 Hz, 3H). 13C (75 MHz)
d 167.77, 138.57, 125.15, 124.96, 67.88, 51.26, 37.62, 32.99, 30.38,
30.31, 29.58, 26.89, 23.84, 14.86. 19F (254 MHz) d272.67 (d, JP–F
= 707 Hz, PF62); MS (ESI): m/z, 253.3 [M2PF62]+; MS (ESI): m/
z, 144.9 [PF62].
3-Methyl-1-(N-butylcarbamoylmethyl)imidazolium PF6
(9h)
A dry flask was charged with 3-methyl-1-(N-butylcarbamoylme-
thyl)imidazolium bromide 7h (120 mg, 0.43 mmol) and acetonitrile
(1 mL) under a nitrogen atmosphere. KPF6 (96 mg, 0.52 mmol) was
added in one portion and the suspension was stirred vigorously for
4 days at rt. The fine white precipitate was filtered quickly in air and
washed with dry acetonitrile (2 3 1 mL). The filtrate and washings
were combined, solvent removed by rotary evaporation then in
vacuo. The product was dried at 60 °C at 0.01 mmHg for 72 h to
give a clear crystalline solid in 99% yield (145 mg, 0.42 mmol). mp
= 64–66 °C; 1H NMR (300 MHz, CD3CN) d 8.46 (s, 1H), 7.36 (s,
2H), 6.78 (bs, 1H, NH), 4.80 (s, 2H), 3.87 (s, 3H), 3.21 (q, J = 7.0
Hz, 2H), 1.60–1.30 (m, 4H), 0.93 (t, J = 7.0 Hz, 3H). 13C (75 MHz)
d 165.87, 138.66, 125.15, 124.69, 52.36, 40.68, 37.51, 32.53, 21.14,
14.55. 19F (254 MHz) d 272.46 (d, JP–F = 707 Hz, PF62); MS
(ESI): m/z, 196.1 [M2PF62]+; MS (ESI): m/z, 144.9 [PF62].
3-Methyl-1-(N-butyl-N-methylcarbamoylmethyl)-
imidazolium PF6 (9i)
This compound was prepared analogously to 9a using 3-methyl-
1-(N-butyl-N-methylcarbamoylmethyl)imidazolium bromide 7i
(265 mg, 0.91 mmol, 1:1.3 mixture of isomers) and KPF6 (185 mg,
1.0 mmol) to give a crystalline solid in 70% yield (225 mg, 0.63
mmol, 1 : 1.3 mixture of isomers). mp = 62–64 °C; * denotes both
isomers. 1H NMR (300 MHz, CD3CN) d 8.42 (s, 1H, minor), 8.40
(s, 1H, major), 7.40–7.30 (m, 2H*), 5.06 (s, 2H, major), 5.03 (s, 2H,
minor), 3.88 (s, 3H*), 3.37 (t, J = 7.0 Hz, 2H, major), 3.28 (t, J =
7.0 Hz, 2H, minor), 3.00 (s, 3H, major), 2.92 (s, 3H, minor),
1.70–1.25 (m, 4H*), 0.99 (t, J = 7.0 Hz, 3H, minor), 0.93 (t, J =
7.0 Hz, 3H, major); 13C (75 MHz) d 165.75 (major), 165.48
(minor), 138.93 (minor), 138.85 (major), 125.51 (minor), 125.45
(major), 124.42*, 51.86 (major), 51.61 (minor), 50.00 (minor),
49.18 (major), 37.50*, 35.05 (major), 34.59 (minor), 31.28 (minor),
30.36 (major), 21.11*, 14.69 (major), 14.65 (minor). 19F (254
MHz) d 272.38 (d, JP–F = 710 Hz, PF62); MS (ESI): m/z, 210.2
[M2PF62]+; MS (ESI): m/z, 144.9 [PF62].
3-Methyl-1-(N,N-diethylcarbamoylmethyl)imidazolium
PF6 (9j)
This compound was prepared analogously to 9a using 3-methyl-
1-(N,N-diethylcarbamoylmethyl)imidazolium bromide 7j (828 mg,
3.0 mmol) and KPF6 (607 mg, 3.3 mmol) to give a crystalline solid
in 66% yield (0.68 g, 2.0 mmol). mp = 64–66 °C; 1H NMR (300
MHz, CD3CN) d 8.43 (s, 1H), 7.33 (s, 2H), 5.04 (s, 2H), 3.88 (s,
3H), 3.37 (q, J = 7.0 Hz, 2H), 3.34 (q, J = 7.0 Hz, 2H), 1.23 (t, J
= 7.0 Hz, 3H), 1.10 (t, J = 7.0 Hz, 3H); 13C (75 MHz) d 164.80,
138.85, 125.47, 124.34, 51.71, 42.50, 42.00, 37.54, 14.65, 13.55;
19F (254 MHz) d 272.8 (d, JP–F = 707 Hz, PF62); MS (ESI): m/z,
196.1 [M2PF62]+; MS (ESI): m/z, 144.9 [PF62].
3-Methyl-1-(methoxycarbonylmethyl)imidazolium NTf2
(10a)
A flask was charged with 3-methyl-1-(methoxycarbonylmethyl)i-
midazolium bromide 7a (702 mg, 3.0 mmol) and distilled water (2
mL). LiNTf2 (947 mg, 3.3 mmol) in distilled water (1 mL) was
added in one portion and the suspension was stirred vigorously for
4 h at rt. The top aqueous layer was removed, the IL washed with
water (3 3 1 mL) then the solvent removed in vacuo. The product
was dried at 60 °C at 0.01 mmHg for 72 h to give a clear viscous oil
in 93% yield (1.21 g, 2.8 mmol). 1H NMR (300 MHz, CD3CN) d
8.49 (s, 1H), 7.39 (bs, 2H), 4.99 (s, 2H), 3.88 (s, 3H), 3.79 (s, 3H).
13C (75 MHz) d 168.23, 138.59, 125.22, 125.09, 121.39 (q, J = 320
Hz, CF3), 54.31, 51.19, 37.64. 19F (254 MHz) d280.15 (CF3). MS
(ESI): m/z, 155.1 [M2NTf22]+; MS (ESI): m/z, 279.9 [NTf22].
3-Methyl-1-(ethoxycarbonylmethyl)imidazolium NTf2
(10b)
This compound was prepared analogously to 10a using 3-methyl-
1-(ethoxycarbonylmethyl)imidazolium bromide 7b (0.53 g, 2.1
mmol) and LiNTf2 (0.60 g, 2.1 mmol) to give a clear viscous oil in
90% yield (0.85 g, 1.9 mmol). 1H NMR (300 MHz, CD3CN) d 8.46
(s, 1H), 7.39 (s, 2H), 4.96 (s, 2H), 4.26 (q, J = 7.0 Hz, 2H), 3.88
(s, 3H), 1.29 (t, J = 7.0 Hz, 3H). 13C (75 MHz) d 167.70, 138.66,
125.19, 124.98, 123.53 (q, J = 320 Hz, CF3), 63.98, 51.33, 37.64,
14.81. 19F (254 MHz) d 280.05 (CF3). MS (ESI): m/z, 169.1
[M2NTf22]+; MS (ESI): m/z, 279.9 [NTf22].
3-Methyl-1-(propoxycarbonylmethyl)imidazolium NTf2
(10c)
This compound was prepared analogously to 10a using 3-methyl-
1-(propoxycarbonylmethyl)imidazolium bromide 7c (0.95 g, 3.6
mmol) and LiNTf2 (1.15 g, 4.0 mmol) to give a clear viscous oil in
92% yield (1.55 g, 3.4 mmol). 1H NMR (300 MHz, CD3CN) d 8.49
(s, 1H), 7.39 (s, 2H), 4.99 (s, 2H), 4.17 (t, J = 7.0 Hz, 2H), 3.87 (s,
3H), 1.68 (tq, J = 7.0, 7.0 Hz, 2H), 0.95 (t, J = 7.0 Hz, 3H). 13C
(75 MHz) d 167.89, 138.82, 125.27, 125.02, 121.44 (q, J = 320 Hz,
CF3), 69.44, 51.32, 37.63, 23.03, 11.03. 19F (254 MHz) d 280.06
(CF3). MS (ESI): m/z, 183.1 [M2NTf22]+; MS (ESI): m/z, 279.9
[NTf22].
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3-Methyl-1-(hexoxycarbonylmethyl)imidazolium NTf2
(10d)
This compound was prepared analogously to 10a using 3-methyl-
1-(hexoxycarbonylmethyl)imidazolium bromide 7d (680 mg, 2.0
mmol) and LiNTf2 (637 mg, 2.2 mmol) to give a clear viscous oil
in 89% yield (0.90 g, 1.8 mmol). 1H NMR (300 MHz, CD3CN) d
8.47 (s, 1H), 7.39 (s, 2H), 4.97 (s, 2H), 4.19 (t, J = 7.0 Hz, 2H),
3.87 (s, 3H), 1.70–1.60 (m, 2H), 1.40–1.30 (m, 6H), 0.90 (t, J = 7.0
Hz, 3H). 13C (75 MHz) d 167.74, 138.60, 125.16, 124.97, 121.39
(q, J = 320 Hz, CF3), 67.90, 51.30, 37.65, 32.53, 29.55, 26.57,
23.70, 14.74. 19F (254 MHz) d280.20 (CF3). MS (ESI): m/z, 225.2
[M2NTf22]+; MS (ESI): m/z, 279.9 [NTf22].
3-Methyl-1-(octoxycarbonylmethyl)imidazolium NTf2
(10g)
This compound was prepared analogously to 10a using 3-methyl-
1-(octoxycarbonylmethyl)imidazolium bromide 7g (548 mg, 1.64
mmol) and LiNTf2 (520 mg, 1.81 mmol) to give a clear viscous oil
in 93% yield (0.81 g, 1.52 mmol). 1H NMR (300 MHz, CD3CN) d
8.48 (s, 1H), 7.39 (s, 2H), 4.97 (s, 2H), 4.20 (t, J = 7.0 Hz, 2H),
3.88 (s, 3H), 1.70–1.60 (m, 2H), 1.40–1.20 (m, 10H), 0.90 (t, J =
7.0 Hz, 3H). 13C (75 MHz) d 167.76, 138.72, 125.21, 124.27,
121.20 (q, J = 320 Hz, CF3), 67.95, 51.28, 37.60, 33.06, 30.43,
30.40, 29.62, 26.96, 23.89, 14.95. 19F (254 MHz) d 280.05 (CF3);
MS (ESI): m/z, 253.3 [M2NTf22]+; MS (ESI): m/z, 279.9
[NTf22].
3-Methyl-1-(N-butyl-N-methylcarbamoylmethyl)-
imidazolium NTf2 (10i)
This compound was prepared analogously to 10a using 3-methyl-
1-(N-butyl-N-methylcarbamoylmethyl)imidazolium bromide 7i
(302 mg, 1.04 mmol, 1 : 1.3 mixture of isomers) and LiNTf2 (329
mg, 1.15 mmol) to give a clear viscous oil in 80% yield (410 mg,
0.84 mmol, 1 : 1.3 mixture of isomers). * denotes both isomers. 1H
NMR (300 MHz, CD3CN) d 8.42 (s, 1H, minor), 8.40 (s, 1H,
major), 7.40–7.30 (m, 2H*), 5.06 (s, 2H, minor), 5.02 (s, 2H,
major), 3.88 (s, 3H*), 3.37 (t, J = 7.0 Hz, 2H, major), 3.28 (t, J =
7.0 Hz, 2H, minor), 3.00 (s, 3H, major), 2.92 (s, 3H, minor),
1.70–1.25 (m, 4H*), 0.99 (t, J = 7.0 Hz, 3H, minor), 0.93 (t, J =
7.0 Hz, 3H, major). 13C (75 MHz) d 165.72 (major), 165.47
(minor), 139.01 (minor), 138.93 (major), 125.55 (minor), 125.48
(major), 124.38*, 121.42* (q, J = 320 Hz, CF3), 51.90 (major),
51.65 (minor), 50.07 (minor), 49.24 (major), 37.49*, 35.07 (major),
34.62 (minor), 31.29 (minor), 30.36 (major), 21.10*, 14.67 (major),
14.61 (minor). 19F (254 MHz) d 279.90 (CF3); MS (ESI): m/z,
210.2 [M2NTf22]+; MS (ESI): m/z, 279.9 [NTf22].
3-Methyl-1-(N,N-diethylcarbamoylmethyl)imidazolium
NTf2 (10j)
This compound was prepared analogously to 10a using 3-methyl-
1-(N,N-diethylcarbamoylmethyl)imidazolium bromide 7j (828 mg,
3.0 mmol) and LiNTf2 (947 mg, 3.3 mmol) to give a crystalline
solid in 83% yield (1.18 g, 2.48 mmol). mp = 43–45 °C; 1H NMR
(300 MHz, CD3CN) d 8.47 (s, 1H), 7.34 (s, 2H), 5.06 (s, 2H), 3.88
(s, 3H), 3.37 (q, J = 7.0 Hz, 2H), 3.34 (q, J = 7.0 Hz, 2H), 1.23 (t,
J = 7.0 Hz, 3H), 1.10 (t, J = 7.0 Hz, 3H). 13C (75 MHz) d 164.81,
138.89, 125.47, 124.33, 121.39 (q, J = 320 Hz, CF3), 51.72, 42.51,
42.00, 37.53, 14.65, 13.55. 19F (254 MHz) d 280.03 (CF3); MS
(ESI): m/z, 196.1 [M2NTf22]+; MS (ESI): m/z, 279.9 [NTf22].
3-Methyl-1-(ethoxycarbonylmethyl)imidazolium N(CN)2
(11b)
A dry flask was charged with 3-methyl-1-(ethoxycarbonylmethyl)i-
midazolium bromide (7b) (1.50 g, 6.0 mmol) and acetonitrile (3
mL) under a nitrogen atmosphere. NaNCNCN (641 mg, 7.2 mmol)
was added in one portion and the suspension was stirred vigorously
for 4 days at rt. The fine white precipitate was filtered quickly in air
and washed with dry acetonitrile (2 3 1 mL). The filtrate and
washings were combined, solvent removed by rotary evaporation
then in vacuo. The product was dried at 60 °C at 0.01 mmHg for 72
h to give a clear viscous hygroscopic oil in 96% yield (1.35 g, 5.73
mmol). 1H NMR (300 MHz, CD3CN) d 9.06 (s, 1H), 7.53 (s, 1H),
7.45 (s, 1H), 5.18 (s, 2H), 4.25 (q, J = 7.0 Hz, 2H), 3.92 (s, 3H),
1.29 (t, J = 7.0 Hz, 3H). 13C (75 MHz) d 167.90, 138.99, 125.02,
124.64, 63.67, 51.26, 37.53, 14.77. Peaks for NCNCN2 not cited.
MS (ESI): m/z, 169.1 [M2NCNCN2]+; MS (ESI): m/z, 66.0
[NCNCN2].
3-Methyl-1-(N-butyl-N-methylcarbamoylmethyl)-
imidazolium N(CN)2 (11i)
This compound was prepared analogously to 11b using 3-methyl-
1-(N-butyl-N-methylcarbamoylmethyl)imidazolium bromide 7i
(208 mg, 0.71 mmol, 1:1.3 mixture of isomers) and NaNCNCN (77
mg, 0.86 mmol) to give a clear viscous hygroscopic oil in 96% yield
(189 mg, 0.68 mmol, 1 : 1.3 mixture of isomers). * denotes both
isomers. 1H NMR (300 MHz, CD3CN) d 8.75 (s, 1H, minor), 8.71
(s, 1H, major), 7.50–7.35 (m, 2H*), 5.20 (s, 2H, major), 5.18 (s, 2H,
minor), 3.90 (s, 3H*), 3.37 (t, J = 7.0 Hz, 2H, major), 3.30 (t, J =
7.0 Hz, 2H, minor), 3.02 (s, 3H, major), 2.92 (s, 3H, minor),
1.70–1.25 (m, 4H*), 0.99 (t, J = 7.0 Hz, 3H, minor), 0.93 (t, J =
7.0 Hz, 3H, major). 13C (75 MHz) d 165.85 (major), 165.54
(minor), 138.99 (minor), 138.85 (major), 125.19 (minor), 125.11
(major), 123.94*, 51.78 (major), 51.43 (minor), 49.78 (minor),
48.75 (major), 37.29*, 35.03 (major), 34.36 (minor), 31.02 (minor),
30.09 (major), 20.85 (minor), 20.77 (major), 14.41*. Peaks for
NCNCN2 not cited. MS (ESI): m/z, 210.2 [M2NCNCN2]+; MS
(ESI): m/z, 66.0 [NCNCN2].
Butyl bromoacetate (12d)42
To a stirred solution of triethylamine (41.6 mL, 300 mmol), butan-
1-ol (18.3 mL, 14.82 g, 200 mmol) and dichloromethane (300 mL)
at 278 °C under a nitrogen atmosphere was added dropwise
bromoacetyl bromide (17.4 mL, 40.37 g, 200 mmol). After stirring
at 278 °C for 3 h the reaction mixture was allowed to warm up to
220 °C and quenched by addition of water (50 mL). The organic
phase was washed with distilled water (3 3 50 mL), saturated
ammonium chloride (3 3 50 mL), saturated sodium bicarbonate (3
3 50 mL) and brine (2 3 50 mL) then dried over magnesium
sulfate, filtered and solvents removed via rotary evaporation. The
crude product (28 g, clean by 1H NMR) was distilled to give a pale
yellow oil in 59% yield (23.1 g, 118 mmol). 1H NMR (300 MHz,
CDCl3) d 4.17 (t, J = 7.0 Hz, 2H), 3.81 (s, 3H), 1.64 (tt, J = 7.0,
7.0 Hz, 2H), 1.40 (tt, J = 7.0, 7.0 Hz, 2H), 0.93 (t, J = 7.0 Hz, 3H).
13C (75 MHz) d. 167.17, 66.01, 30.33, 25.77, 18.87, 13.49.
Pentylbromoacetate (12e)42,43
This compound was prepared analogously to butylbromoacetate
using pentan-1-ol (21.7 mL, 17.6 g, 200 mmol) to give a pale
yellow oil in 72% yield (29.9 g, 143 mmol). 1H NMR (300 MHz,
CDCl3) d 4.16 (t, J = 7.0 Hz, 2H), 3.81 (s, 3H), 1.64 (tt, J = 7.0,
7.0 Hz, 2H), 1.45–1.25 (m, 4H), 0.89 (t, J = 7.0 Hz, 3H). 13C (75
MHz) d. 167.16, 66.28, 27.99, 27.76, 25.77, 22.12, 13.79.
Hexylbromoacetate (12f)
This compound was prepared analogously to butylbromoacetate
using triethylamine (20.8 mL, 150 mmol), hexan-1-ol (12.4 mL,
10.2 g, 100 mmol), dichloromethane (200 mL) and bromoacetyl
bromide (8.7 mL, 20.2 g, 100 mmol) to give a crude product (21.6
g) which was distilled to give a colourless oil in 65% yield (14.5 g,
65 mmol). 1H NMR (300 MHz, CDCl3) d 4.17 (t, J = 7.0 Hz, 2H),
3.82 (s, 3H), 1.64 (tt, J = 7.0, 7.0 Hz, 2H), 1.40–1.20 (m, 6H), 0.89
(t, J = 7.0 Hz, 3H). 13C (75 MHz) d. 167.20, 66.34, 31.24, 28.28,
25.77, 25.30, 22.38, 13.84. NMR data in agreement with lit-
erature.44
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Octylbromoacetate (12g)
This compound was prepared analogously to butylbromoacetate
using triethylamine (20.8 mL, 150 mmol), octan-1-ol (15.8 mL,
13.0 g, 100 mmol), dichloromethane (200 mL) and bromoacetyl
bromide (8.7 mL, 20.2 g, 100 mmol) to give a crude product (18.7
g) which was distilled to give a colourless oil in 24% yield (6.0 g,
24 mmol). 1H NMR (300 MHz, CDCl3 d 4.16 (t, J = 7.0 Hz, 2H),
3.82 (s, 3H), 1.64 (tt, J = 7.0, 7.0 Hz, 2H), 1.40–1.20 (m, 10H),
0.88 (t, J = 7.0 Hz, 3H). 13C (75 MHz) d 167.13, 66.27, 31.62,
29.00, 29.01, 28.30, 25.74, 25.62, 22.48, 13.91. NMR data in
agreement with literature.45
N-Butyl-2-bromoacetamide (12h)46
This compound was prepared analogously to butylbromoacetate
using triethylamine (20.8 mL, 150 mmol), butylamine (9.8 mL, 7.3
g, 100 mmol), dichloromethane (200 mL) and bromoacetyl
bromide (8.7 mL, 20.2 g, 100 mmol) to give a crude product (18.0
g) which was distilled to give a light brown oil, which crystallized
on standing, in 39% yield (7.5 g, 39 mmol). Mp = 35–37 °C. Lit.
Mp = 38–39 °C.46 1H NMR (300 MHz, CDCl3) d 6.50 (bs, 1H,
NH), 3.87 (s, 2H), 3.28 (q, J = 7.0 Hz, 2H), 1.52 (tt, J = 7.0, 7.0
Hz, 2H), 1.37 (tt, J = 7.0, 7.0 Hz, 2H), 0.93 (t, J = 7.0 Hz, 3H). 13C
(75 MHz) d 165.35, 39.85, 31.18, 29.17, 19.86, 13.55.
N-Butyl-N-methyl-2-bromoacetamide (12i)42
This compound was prepared analogously to butylbromoacetate
using triethylamine (20.8 mL, 150 mmol), N-methyl-butylamine
(11.8 mL, 8.72 g, 100 mmol), dichloromethane (200 mL) and
bromoacetyl bromide (8.7 mL, 20.2 g, 100 mmol) to give a crude
product (21.0 g) which was distilled to give a pale yellow oil in 54%
yield (11.37 g, 54 mmol). 1H NMR (300 MHz, CDCl3) d 3.84 (s,
2H, minor), 3.83 (s, 2H, major), 3.35 (t, J = 7.0 Hz, 2H, major),
3.30 (t, J = 7.0 Hz, 2H, minor), 3.04 (s, 3H, major), 2.92 (s, 3H,
minor), 1.65–1.25 (m, 4H, major and minor), 0.94 (t, J = 7.0 Hz,
3H, minor), 0.91 (t, J = 7.0 Hz, 3H, major). 13C (75 MHz) d
166.30, 50.55, 47.88, 35.89, 33.61, 30.41, 28.84, 26.57, 25.89,
19.75, 13.66.
N,N-Diethyl-2-bromoacetamide (12j)
This compound was prepared analogously to butylbromoacetate
using triethylamine (20.8 mL, 150 mmol), diethylamine (10.4 mL,
7.30 g, 100 mmol), dichloromethane (200 mL) and bromoacetyl
bromide (8.7 mL, 20.2 g, 100 mmol) to give a crude product (14.5
g) which was distilled to give a pale yellow oil in 31% yield (6.01
g, 31 mmol). 1H NMR (300 MHz, CDCl3) d 3.83 (s, 2H), 3.378 (q,
J = 7.0 Hz, 2H), 3.383 (q, J = 7.0 Hz, 2H), 1.25 (t, J = 7.0 Hz,
3H), 1.13 (t, J = 7.0 Hz, 3H). 13C (75 MHz) d 165.65, 42.78, 40.36,
26.39, 14.20, 12.34. NMR data in agreement with literature.47
Closed Bottle Test
Sodium n-dodecyl sulfate (SDS) was used as reference substance.
Solutions containing 2 mg L21 of the test ionic liquids and the
reference chemical as sole sources of organic carbon were
prepared, separately, in previously aerated mineral medium. The
solutions were then inoculated with secondary effluent collected
from an activated sludge treatment plant and each well-mixed
solution was carefully dispensed into a series of BOD bottles so that
all the bottles were completely full. A control with inoculum, but
without test chemicals was run parallel for the determination of
oxygen blanks. Duplicate bottles of each series were analysed
immediately for dissolved oxygen and the remaining bottles were
incubated at 20 °C±1 °C in the dark. Bottles of all series were
withdrawn in duplicate for dissolved oxygen analysis over the
28-day incubation period. The biodegradation after n days was
expressed as the ratio of the biochemical oxygen demand (BOD) to
the chemical oxygen demand (COD) both of them expressed as mg
O2/mg compound. The chemical oxygen demand was determined
by the dichromate reflux method.48 For the calculation of the
biochemical oxygen demand the determined oxygen depletions
were divided by the concentration of ionic liquid.
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